Business
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that Chief Commercial Officer, Gael Forterre, has issued a commercial update on Volition's Nu.Q® NETs product.
About this update from Volitionrx Limited
[{"type":"text","content":"HENDERSON, Nev., May 7, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that Chief Commercial Officer, Gael Forterre, has issued a commercial update on Volition's Nu.Q® NETs product.","length":283,"tagName":"p"},{"type":"text","content":"A Message from our Chief Commercial Officer","length":43,"tagName":"p"},{"type":"text","content":"As was stated in our shareholder update recently, 2025 is a pivotal year for Volition as we focus on commercializing our groundbreaking Nu.Q® platform in the human diagnostics market. Today, I would like to focus on the large, and very broad Nu.Q® NETs (NETosis) opportunity.","length":280,"tagName":"p"},{"type":"text","content":"Our efforts on this are two-pronged:","length":36,"tagName":"p"},{"type":"text","content":"1. Licensing","length":48,"tagName":"p"},{"type":"text","content":"To negotiate with large multi-national companies to launch our Nu.Q® NETs test on their extensive base of installed machines already servicing every hospital in the world, with existing labs and sales teams. The focus of these discussions is centered around significant unmet needs in sepsis and coagulation. The aim, as we successfully achieved in the vet space, is to operate a low CapEx / low OpEx model; Low CapEx for our partners in that they already have a global footprint of their automated systems and low OpEx for Volition as the majority of functions (sales, regulatory and clinical affairs, sales, marketing) are conducted by our partners. Volition simply provides access to its intellectual property and the supply of key components for the test itself. We believe this is a win-win for everyone, allowing broad adoption worldwide with limited investment and giving these large companies a new revenue stream from their installed base.","length":948,"tagName":"p"},{"type":"text","content":"I am delighted to report we are in confidential discussions regarding the licensing and supply of our Nu.Q® NETs assay with seven international companies. Notably, the combined market value of six of these companies is just under $600billion1, underscoring the significant global strength, potential reach and impact our technology could achieve through such partnerships.","length":372,"tagName":"p...